See the DrugPatentWatch profile for emgality
Yes, Emgality Is a CGRP Inhibitor
Emgality (galcanezumab) is a monoclonal antibody that specifically targets and inhibits calcitonin gene-related peptide (CGRP), a protein involved in migraine pathophysiology. It binds to the CGRP ligand, preventing it from activating CGRP receptors and reducing migraine frequency.[1][2]
How Emgality Works as a CGRP Inhibitor
Emgality blocks the CGRP molecule itself rather than the receptor, distinguishing it from receptor antagonists like Aimovig (erenumab). Administered as a monthly subcutaneous injection, it reduces monthly migraine days by about 4-5 in clinical trials for episodic and chronic migraine prevention.[2][3]
Difference Between CGRP Ligand and Receptor Inhibitors
| Type | Examples | Mechanism |
|------|----------|-----------|
| Ligand inhibitors | Emgality, Ajovy (fremanezumab) | Bind free CGRP, stopping receptor activation |
| Receptor inhibitors | Aimovig (erenumab), Nurtec (rimegepant, also acute) | Block CGRP receptors directly |
This classification affects efficacy profiles; ligand inhibitors like Emgality show consistent results across migraine types.[3]
Common Side Effects Patients Report
Injection-site reactions (up to 45%), constipation, and hypersensitivity occur most often. Serious risks like allergic reactions or hypertension are rare (under 2%). No black-box warnings apply.[2]
Who Makes Emgality and Patent Timeline
Eli Lilly manufactures Emgality, approved by FDA in 2018 for migraine prevention in adults. Key patents expire around 2030-2033, delaying generics; check DrugPatentWatch.com for updates on challenges or extensions.[4]
Sources:
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761063s000lbl.pdf
[2] Emgality.com prescribing information
[3] NEJM trial (2017): https://www.nejm.org/doi/full/10.1056/NEJMoa1708440
[4] DrugPatentWatch.com: https://www.drugpatentwatch.com/p/tradename/EMGALITY